PE20090239A1 - ANTAGONISTAS CRIg - Google Patents

ANTAGONISTAS CRIg

Info

Publication number
PE20090239A1
PE20090239A1 PE2008000774A PE2008000774A PE20090239A1 PE 20090239 A1 PE20090239 A1 PE 20090239A1 PE 2008000774 A PE2008000774 A PE 2008000774A PE 2008000774 A PE2008000774 A PE 2008000774A PE 20090239 A1 PE20090239 A1 PE 20090239A1
Authority
PE
Peru
Prior art keywords
crig
scfv
fab
clearing
refers
Prior art date
Application number
PE2008000774A
Other languages
English (en)
Inventor
Lookeren Campagne Menno Van
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39645433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090239(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20090239A1 publication Critical patent/PE20090239A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN ANTICUERPO MONOCLONAL HUMANIZADO O UN FRAGMENTO DEL MISMO SELECCIONADO DE Fab, Fab', F(ab')2, scFv, (scFv)2 O dAb, QUE ES UN ANTAGONISTA DEL RECEPTOR ASOCIADO AL MACROFAGO CRIg QUE BLOQUEA EL ENLACE DE UN POLIPEPTIDO CRIg INHIBIENDO LA ENTRADA CELULAR DEPENDIENTE DEL COMPLEMENTO MEDIADA POR CRIg DE UN PATOGENO INTRACELULAR TAL COMO UN VIRUS DE ARN O ADN, PARASITO, BACTERIA, HONGO O PRION, O DEPURANDO UN PATOGENO INTRACELULAR DE LA CIRCULACION. DICHO ANTICUERPO ES ANTI-CRIg MONOCLONAL SELECCIONADO DE 14G8, 3D10 O 2H1. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHO ANTICUERPO ANTI-CRIg SIENDO UTIL ADEMAS EN LA PREVENCION DE LA DEPURACION NO DESEADA DE ERITROCITOS Y PLAQUETAS
PE2008000774A 2007-05-01 2008-04-30 ANTAGONISTAS CRIg PE20090239A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91534007P 2007-05-01 2007-05-01

Publications (1)

Publication Number Publication Date
PE20090239A1 true PE20090239A1 (es) 2009-03-19

Family

ID=39645433

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000774A PE20090239A1 (es) 2007-05-01 2008-04-30 ANTAGONISTAS CRIg

Country Status (16)

Country Link
US (1) US20090162356A1 (es)
EP (1) EP2152749A1 (es)
JP (1) JP2010526076A (es)
KR (1) KR20100018523A (es)
CN (1) CN101675078A (es)
AR (1) AR066375A1 (es)
AU (1) AU2008247958A1 (es)
BR (1) BRPI0810926A2 (es)
CA (1) CA2682835A1 (es)
CL (1) CL2008001238A1 (es)
IL (1) IL201165A0 (es)
MX (1) MX2009011407A (es)
PE (1) PE20090239A1 (es)
RU (1) RU2009144280A (es)
WO (1) WO2008137338A1 (es)
ZA (1) ZA200906812B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
SI2280996T1 (sl) * 2008-05-06 2016-12-30 Genentech, Inc. Afinitetno dozorele variante CRIg
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
CN105924515B (zh) * 2016-04-25 2019-06-14 中国人民解放军第三军医大学 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110944666A (zh) 2017-06-26 2020-03-31 博奥泰克尼公司 杂交瘤克隆、vsig-4的单克隆抗体，以及制备和使用的方法
KR20210087028A (ko) * 2018-09-28 2021-07-09 주식회사 유틸렉스 항-인간 vsig4 항체 및 이의 용도
US20220233756A1 (en) * 2019-05-17 2022-07-28 George A. Herzlinger Methods and systems for treating microbial disease
AU2020342910A1 (en) * 2019-09-04 2022-04-07 Pierre Fabre Medicament Anti-VSIG4 antibody or antigen binding fragment and uses thereof
TW202302645A (zh) 2021-03-03 2023-01-16 法商皮爾法伯製藥公司 抗vsig4抗體或抗原結合片段及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders

Also Published As

Publication number Publication date
CN101675078A (zh) 2010-03-17
BRPI0810926A2 (pt) 2014-11-04
MX2009011407A (es) 2009-11-05
US20090162356A1 (en) 2009-06-25
EP2152749A1 (en) 2010-02-17
AU2008247958A1 (en) 2008-11-13
AR066375A1 (es) 2009-08-12
WO2008137338A1 (en) 2008-11-13
KR20100018523A (ko) 2010-02-17
ZA200906812B (en) 2010-12-29
IL201165A0 (en) 2010-05-17
RU2009144280A (ru) 2011-06-10
JP2010526076A (ja) 2010-07-29
CL2008001238A1 (es) 2008-11-07
CA2682835A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
PE20090239A1 (es) ANTAGONISTAS CRIg
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
CR20120127A (es) Anticuerpos monoclonales
PE20091029A1 (es) Anticuerpos anti-alfa 5 beta 1
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
NZ743713A (en) Human immunodeficiency virus neutralizing antibodies
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
MY159517A (en) A monoclonal antibody and a method thereof
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
EA201391159A1 (ru) Hla-рестриктированные пептидоспецифические антигенсвязывающие белки
RS53291B (en) BETA 1-42 SPECIFIC MONOCLONIC ANTIBODIES WITH THERAPEUTIC PROPERTIES
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas
WO2016154047A3 (en) Monoclonal antigen-binding proteins to intracellular oncogene products
MX2013012201A (es) Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.
DE602006013029D1 (de) Anti-egfr-antikörper
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
RS54624B1 (en) MONOCLONIC ANTIBODIES AGAINST GLIPICAN-3
MA34520B1 (fr) Anticorps se liant à la myostatine, compositions et procédés
RS54056B1 (en) ANTI-CD38 HUMAN ANTIBODIES AND THEIR USES
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
ES2584956T3 (es) Anticuerpos anti-CD40 y usos de los mismos
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed